STOCK TITAN
  1. Home
  2. News
  3. GSK

GSK Plc - GSK STOCK NEWS

Welcome to our dedicated news page for GSK Plc (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GSK Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GSK Plc's position in the market.

News
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
Rhea-AI Summary
GSK announces positive results from the RUBY phase III trial for dostarlimab-gxly in combination with chemotherapy and niraparib for endometrial cancer. The trial shows significant improvements in overall survival and progression-free survival in the overall population and MMRp/MSS population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
Rhea-AI Summary
GSK announces $2 million commitment in 2024 to boost adult immunization rates and health equity under COiMMUNITY Initiative. New resources and data show adult vaccination rates returning to pre-pandemic levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News
GSK Exercises Option to License Elsie Biotechnologies’ Discovery Platform to Find and Develop Novel Oligonucleotides
Rhea-AI Summary
Elsie Biotechnologies, Inc. announces GSK's licensing of their discovery platform after a successful research collaboration, potentially leading to development and commercial milestones. The agreement allows GSK to utilize Elsie's platform for oligonucleotide drug discovery, showcasing the platform's potential for next-generation RNA medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none
News
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
Rhea-AI Summary
GSK plc has announced that the US FDA has accepted an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, this would be the first vaccine available to help protect this population. The application is supported by positive results from a phase III trial evaluating the immune response and safety of the RSV vaccine in adults aged 50-59. The US FDA has set a Prescription Drug User Fee Act action date of June 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
News
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
Rhea-AI Summary
Elegen and GSK have entered into a multi-year collaboration and licensing agreement, allowing GSK to utilize Elegen's cell-free DNA manufacturing technology in the development of vaccines and medicines. The agreement includes upfront fees, purchase commitments of Elegen's ENFINIA DNA, near-term milestone payments, and a potential equity investment in Elegen by GSK, amounting to up to $35 million in near-term financial and development support and fees. Elegen's ENFINIA DNA, launched in March of last year, delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. The technology is expected to save significant time and resources in the development of genetic medicines, potentially including mRNA, cell, and viral gene therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News
GSK Enters Agreement to Acquire Aiolos Bio
Rhea-AI Summary
GSK plc (GSK) acquires Aiolos Bio, Inc. (Aiolos) for $1 billion upfront, expanding its respiratory pipeline with AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway. AIO-001 has the potential to redefine the standard-of-care with dosing every six months, reaching a broader portion of asthma patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
acquisition
News
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
Rhea-AI Summary
GSK plc (LSE/NYSE: GSK) announced the recipients of the inaugural grant program of the COiMMUNITY Initiative, a multipronged effort to support the design of a more systematic, collaborative, and equitable approach to increasing adult immunization rates in the US. Each grant-funded project is receiving between $50,000 and $175,000 out of a total $1 million in funding to address long-standing barriers to adult immunization in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
News
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
Rhea-AI Summary
GSK plc (LSE/NYSE: GSK) Launches Mapping Myelofibrosis Initiative in Partnership with Thom Filicia to Raise Awareness for Myelofibrosis (MF) - a Complex Blood Cancer Affecting 25,000 People in the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
none
-
News
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
Rhea-AI Summary
GSK announces positive preliminary results from phase III trial of AREXVY vaccine in adults aged 50 to 59 at increased risk for RSV disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
News
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
Rhea-AI Summary
GSK's Ojjaara (momelotinib) receives FDA approval for the treatment of myelofibrosis patients with anemia, addressing key manifestations of the disease. Myelofibrosis affects approximately 25,000 patients in the US. Limited treatment options have led to high discontinuation rates and poor prognosis for patients with anemia. Ojjaara is the only approved medicine for both newly diagnosed and previously treated myelofibrosis patients with anemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock GSK logo
GSK Plc

NYSE:GSK

GSK Rankings

#131 Ranked by Market Cap
#1748 Ranked by Stock Gains
#854 Ranked by Dividends

GSK Stock Data

83.44B
3.91B
0.06%
14.42%
0.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Brentford

About GSK

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.